Published in Hospital Business Week, November 26th, 2006
Results of a randomized, prospective, open-label, multi-center study assessing clinical outcomes based on the number of nebulizations throughout the duration of the hospital stay and cost-effectiveness in hospitalized patients administered either Xopenex Inhalation Solution (n=241) or racemic albuterol (n=238) by nebulization were presented. Upon admission to the hospital,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.